

Update from TROG

10 May 2012

Global Harmonisation Group (GHG) Meeting

Annette Haworth

(on behalf of Deidre Cornes, Tomas Kron, Martin Ebert and TROG)



Summary of activities relevant to GHG



- Trial portfolio
 - XXX Open trials
 - YYY Trials under development
 - ZZZ trials have international collaboration
- Participation on Govt. funded project to develop framework for new technology assessment
- Australian Clinical Dosimetry Service (ERDA for Australia)
- Incorporation of ICRU 83 recommendations
- Development of QA standards for new technology
- SWAN developments (Martin Ebert)

Framework for new technology assessment




ANROTAT:

- Project objective: Develop framework for Assessment of New Radiation Oncology Technology And Treatments
- 2-year project, ends June 2012
- Commissioned by Australian Government in recognition funding not keeping pace with technology
- Framework tested (IMRT x 3 + IGRT)

ANROTAT 'spin-offs'



- Framework testing:
 - IMRT vs 3DCRT in NPC, anal cancer and prostate bed
 - IGRT prostate
 - Development of decision analytic model (health economics)
 - ICRU 83 recommendations (see next slide)
 - All participating sites required to participate in an IMRT dosimetric audit



Registries



- ANROTAT project piloted registry
- Relevance for clinical trials....

Practical Radiation Oncology (2012) 2, 10–17

practical radiation oncology
pro
www.practicalradonc.org

Special Article

Developing a national radiation oncology registry: From acorns to oaks

Jatinder R. Palta PhD^{a,*}, Jason A. Efstathiou MD, PhD^b, Justin E. Bekelman MD^c, Sasa Mutic PhD^d, Carl R. Bogardus MD^e, Todd R. McNutt PhD^f, Peter E. Gabriel MD^c, Colleen A. Lawton MD^g, Anthony L. Zietman MD^b, Christopher M. Rose MD^h

Australian Clinical Dosimetry Service (ERDA for Australia)



- Government sponsored for 3 years at our standards lab (ARPANSA)
- Free audits (Level I – III)
- Clinical Advisory Group includes TROG representation
- Aim to be self sufficient after 3 years?
- <http://www.arpansa.gov.au/services/ACDS/index.cfm>



Dr Ivan Williams,
Director



Incorporation of ICRU 83 recommendations

➤ Dose Reporting:

- *Target volumes*: as a minimum:
 - mean dose, **D50%** (median dose)
 - **D2%**, **D98%** (near-max/min)
 - **Dv%** (ie dose volume parameters)
- **OAR**: as a minimum:
 - mean dose
 - **D2%** (serial-like organs)
 - Dose volume parameters (parallel-like organs)



Incorporation of ICRU 83 recommendations

➤ Challenges:

- Trials that permit a range of techniques
 - Define prescription and planning objectives common to all techniques that provide equivalent outcomes as applicable
 - Eg Monaco produces hot plans – anyone else had trouble with this??

➤ What about naming conventions?



Are all trial groups adopting this?



International Journal of
Radiation Oncology
biology • physics

www.redjournal.org

Physics Contribution

Standardizing Naming Conventions in Radiation Oncology

Lakshmi Santanam, Ph.D.,* Coen Hurkmans, Ph.D.,[†] Sasa Mutic, Ph.D.,*
Corine van Vliet-Vroegindeweyj, Ph.D.,[‡] Scott Brame, Ph.D.,* William Straube, M.S.,*
James Galvin, D.Sc.,[‡] Prabhakar Tripuraneni, M.D.,[§] Jeff Michalski, M.D.,*
and Walter Bosch, D.Sc.*,[¶]

Development of QA standards for new technology



- IMRT - well advanced
- VMAT – in development
- IGRT – advanced but not formalised
- PET – in development
- Motion management – advanced but not formalised
- Brachy, SRS etc – under developed due to lack of demand